Comparative Pharmacology

Head-to-head clinical analysis: HEPARIN SODIUM 10 000 UNITS IN SODIUM CHLORIDE 0 9 versus MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER.

Peer-Reviewed Evidence

Differential Analysis

HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9% vs MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.

HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9%

Electrolyte

Category A/B

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

Electrolyte

Category C

Head-to-Head

Clinical Matrix

Mechanism of Action

Heparin binds to antithrombin III (ATIII), inducing a conformational change that accelerates ATIII-mediated inactivation of coagulation factors IIa (thrombin), Xa, IXa, XIa, and XIIa, thereby inhibiting thrombus formation and propagation.

Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.

Clinical Dosing

Intravenous: Initial bolus 80 units/kg, then continuous infusion 18 units/kg/hour; subcutaneous: 5000 units every 8-12 hours.

1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).

Direct Interaction

None Documented